-
1
-
-
0024240878
-
Regimen-related toxicity in patients undergoing bone marrow transplantation
-
Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
-
(1988)
J Clin Oncol
, vol.6
, pp. 1562-1568
-
-
Bearman, S.I.1
Appelbaum, F.R.2
Buckner, C.D.3
Petersen, F.B.4
Fisher, L.D.5
Clift, R.A.6
-
2
-
-
0027478056
-
Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients
-
McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: A cohort study of 355 patients. Ann Intern Med 1993; 118: 255-267.
-
(1993)
Ann Intern Med
, vol.118
, pp. 255-267
-
-
McDonald, G.B.1
Hinds, M.S.2
Fisher, L.D.3
Schoch, H.G.4
Wolford, J.L.5
Banaji, M.6
-
3
-
-
0032533633
-
Incidence and outcome of hepatic venoocclusive disease after blood or marrow transplantation: A prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party
-
Carreras E, Bertz H, Arcese W, Vernant JP, Tomas JF, Hagglund H et al Incidence and outcome of hepatic venoocclusive disease after blood or marrow transplantation: A prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 1998; 92: 3599-3604.
-
(1998)
Blood
, vol.92
, pp. 3599-3604
-
-
Carreras, E.1
Bertz, H.2
Arcese, W.3
Vernant, J.P.4
Tomas, J.F.5
Hagglund, H.6
-
4
-
-
0032620465
-
Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: Incidence, risk factors, and outcome
-
Lee JL, Gooley T, Bensinger W, Schiffman K, McDonald GB. Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: Incidence, risk factors, and outcome. Biol Blood Marrow Transplant 1999; 5: 306-315.
-
(1999)
Biol Blood Marrow Transplant
, vol.5
, pp. 306-315
-
-
Lee, J.L.1
Gooley, T.2
Bensinger, W.3
Schiffman, K.4
McDonald, G.B.5
-
5
-
-
9144249706
-
Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: A study of 193 patients
-
Hogan WJ, Maris M, Storer B, Sandmaier BM, Maloney DG, Schoch HG et al. Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: A study of 193 patients. Blood 2004; 103: 78-84.
-
(2004)
Blood
, vol.103
, pp. 78-84
-
-
Hogan, W.J.1
Maris, M.2
Storer, B.3
Sandmaier, B.M.4
Maloney, D.G.5
Schoch, H.G.6
-
6
-
-
0029011780
-
The syndrome of hepatic veno-occlusive disease after marrow transplantation
-
Bearman SI. The syndrome of hepatic veno-occlusive disease after marrow transplantation. Blood 1995; 85: 3005-3020.
-
(1995)
Blood
, vol.85
, pp. 3005-3020
-
-
Bearman, S.I.1
-
7
-
-
0037112813
-
Hemostatic complications in bone marrow transplantation: A retrospective analysis of 447 patients
-
Pihusch R, Salat C, Schmidt E, Gohring P, Pihusch M, Hiller E et al Hemostatic complications in bone marrow transplantation: A retrospective analysis of 447 patients. Transplantation 2002; 74: 1303-1309.
-
(2002)
Transplantation
, vol.74
, pp. 1303-1309
-
-
Pihusch, R.1
Salat, C.2
Schmidt, E.3
Gohring, P.4
Pihusch, M.5
Hiller, E.6
-
8
-
-
0032410481
-
Prevention and treatment of hepatic venocclusive disease after high-dose cytoroductive therapy
-
Richardson P, Bearman SI. Prevention and treatment of hepatic venocclusive disease after high-dose cytoroductive therapy. Leuk Lymphoma 1998; 31: 267-277.
-
(1998)
Leuk Lymphoma
, vol.31
, pp. 267-277
-
-
Richardson, P.1
Bearman, S.I.2
-
9
-
-
20244365292
-
Defibrotide for the treatment of hepatic veno-occlusive disease: Results of the European compassionate-use study
-
Chopra R, Eaton JD, Grassi A, Potter M, Shaw B, Salat C et al. Defibrotide for the treatment of hepatic veno-occlusive disease: Results of the European compassionate-use study. Br J Haematol 2000; 111: 1122-1129.
-
(2000)
Br J Haematol
, vol.111
, pp. 1122-1129
-
-
Chopra, R.1
Eaton, J.D.2
Grassi, A.3
Potter, M.4
Shaw, B.5
Salat, C.6
-
10
-
-
0037114746
-
Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: Response without significant toxicity in a high-risk population and factors predictive of outcome
-
Richardson PG, Murakami C, An Z, Warren D, Momtaz P, Hoppensteadt D et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: Response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002; 100: 4337-4343.
-
(2002)
Blood
, vol.100
, pp. 4337-4343
-
-
Richardson, P.G.1
Murakami, C.2
An, Z.3
Warren, D.4
Momtaz, P.5
Hoppensteadt, D.6
-
11
-
-
10744221943
-
Difibrotide in the treatment of children with veno-occlusive disease- (VOD): A retrospective multicentre study demonstrates therapeutic efficacy upon early intervention
-
Corbacioglu S, Greil J, Peters C, Wulffraat N, Laws HJ, Dilloo D et al. Difibrotide in the treatment of children with veno-occlusive disease- (VOD): A retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transplant 2004; 33: 189-195.
-
(2004)
Bone Marrow Transplant
, vol.33
, pp. 189-195
-
-
Corbacioglu, S.1
Greil, J.2
Peters, C.3
Wulffraat, N.4
Laws, H.J.5
Dilloo, D.6
-
12
-
-
1942456498
-
Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation
-
Chalandon Y, Roosnek E, Mermillod B, Newton A, Ozsahin H, Wacker P et al. Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2004; 10: 347-354.
-
(2004)
Biol Blood Marrow Transplant
, vol.10
, pp. 347-354
-
-
Chalandon, Y.1
Roosnek, E.2
Mermillod, B.3
Newton, A.4
Ozsahin, H.5
Wacker, P.6
-
13
-
-
33749443746
-
Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with defibrotide
-
Corbacioglu S, Honig M, Lahr G, Stohr S, Berry G, Friedrich W et al Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with defibrotide. Bone Marrow Transplant 2006; 38: 547-553.
-
(2006)
Bone Marrow Transplant
, vol.38
, pp. 547-553
-
-
Corbacioglu, S.1
Honig, M.2
Lahr, G.3
Stohr, S.4
Berry, G.5
Friedrich, W.6
-
14
-
-
34347407602
-
Prophylactic defibrotide in allogeneic stem cell transplantation: Minimal morbidity and zero mortality from veno-occlusive disease
-
Dignan F, Gujral D, Ethell M, Evans S, Treleaven J, Morgan G et al Prophylactic defibrotide in allogeneic stem cell transplantation: minimal morbidity and zero mortality from veno-occlusive disease. Bone Marrow Transplant 2007; 40: 79-82.
-
(2007)
Bone Marrow Transplant
, vol.40
, pp. 79-82
-
-
Dignan, F.1
Gujral, D.2
Ethell, M.3
Evans, S.4
Treleaven, J.5
Morgan, G.6
-
15
-
-
34249947838
-
Selective susceptibility of hepatic endotbelial cells to dacarbazine toxicity, a model for hepatic venoocclusive disease
-
DeLeve LD, Kaplowitz N. Selective susceptibility of hepatic endotbelial cells to dacarbazine toxicity, a model for hepatic venoocclusive disease. Hepatology 1991; 14: 161A.
-
(1991)
Hepatology
, vol.14
-
-
DeLeve, L.D.1
Kaplowitz, N.2
-
16
-
-
0029809978
-
Cellular target of cyclophosphamide toxicity in the murine liver: Role of glutathione and site of metabolic activation
-
DeLeve LD. Cellular target of cyclophosphamide toxicity in the murine liver: Role of glutathione and site of metabolic activation. Hepatology 1996; 24: 830-837.
-
(1996)
Hepatology
, vol.24
, pp. 830-837
-
-
DeLeve, L.D.1
-
17
-
-
0034021677
-
The effect of busulphan on the pharmaco-kinetics of cyclophosphamide and its 4-hydroxy metabolite: Time interval influence on therapeutic efficacy and therapy-related toxicity
-
Hassan M, Ljungman P, Ringden O, Hassan Z, Oberg G, Nilsson C et al The effect of busulphan on the pharmaco-kinetics of cyclophosphamide and its 4-hydroxy metabolite: Time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant 2000; 25: 915-924.
-
(2000)
Bone Marrow Transplant
, vol.25
, pp. 915-924
-
-
Hassan, M.1
Ljungman, P.2
Ringden, O.3
Hassan, Z.4
Oberg, G.5
Nilsson, C.6
-
18
-
-
33646504460
-
High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy
-
de Jonge ME, Huitema AD, Beijnen JH, Rodenhuis S. High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy. Br J Cancer 2006; 94: 1226-1230.
-
(2006)
Br J Cancer
, vol.94
, pp. 1226-1230
-
-
de Jonge, M.E.1
Huitema, A.D.2
Beijnen, J.H.3
Rodenhuis, S.4
-
19
-
-
0028593325
-
Parameters of.the fibrinolytic system in patients undergoing BMT: Elevation of. PAI-1 in veno-occlusive disease
-
Salat C, Holler E, Reinhardt B, Kolb HJ, Seeber B, Ledderose G et al Parameters of.the fibrinolytic system in patients undergoing BMT: elevation of. PAI-1 in veno-occlusive disease. Bone Marrow Transplant 1994; 14: 747-750.
-
(1994)
Bone Marrow Transplant
, vol.14
, pp. 747-750
-
-
Salat, C.1
Holler, E.2
Reinhardt, B.3
Kolb, H.J.4
Seeber, B.5
Ledderose, G.6
-
20
-
-
4243653730
-
Elevation of PAI-1 levels in BMT-associated VOD and changes seen with the use of defibrotide
-
Richardson P, Krishnan A, Wheelef C, Hoppensteadt D, Tuchin J, Fyfe H et al. Elevation of PAI-1 levels in BMT-associated VOD and changes seen with the use of defibrotide. Blood 1996; 88: 458a.
-
(1996)
Blood
, vol.88
-
-
Richardson, P.1
Krishnan, A.2
Wheelef, C.3
Hoppensteadt, D.4
Tuchin, J.5
Fyfe, H.6
-
21
-
-
4243382376
-
Elevation of tissue factor pathway inhibitor [TFPI], thrombomodulin [TM] and plasminogen activator inhibitor-1 [PAI-1] levels in stem cell transplant [SCT]-associated veno-occlusive disease [VOD] and changes seen with the use of defibrotide [DF]
-
Richardson P, Hoppensteadt D, Elias A, Frei III E, Iacobelli M, Guinan E et al. Elevation of tissue factor pathway inhibitor [TFPI], thrombomodulin [TM] and plasminogen activator inhibitor-1 [PAI-1] levels in stem cell transplant [SCT]-associated veno-occlusive disease [VOD] and changes seen with the use of defibrotide [DF]. Blood 1997; 90: 219a.
-
(1997)
Blood
, vol.90
-
-
Richardson, P.1
Hoppensteadt, D.2
Elias, A.3
Frei III, E.4
Iacobelli, M.5
Guinan, E.6
-
22
-
-
0003717434
-
Elevation of endothelial stress products and trends seen in patients with severe veno-occlusive disease treated with defibrotide
-
Richardson PG, Hoppensteadt D, Elias AD, Kinchla N, Warren D, Iacobelli M et al. Elevation of endothelial stress products and trends seen in patients with severe veno-occlusive disease treated with defibrotide. Thromb Hemost 1999; 3185 (Suppl): 628.
-
(1999)
Thromb Hemost
, vol.3185
, Issue.SUPPL.
, pp. 628
-
-
Richardson, P.G.1
Hoppensteadt, D.2
Elias, A.D.3
Kinchla, N.4
Warren, D.5
Iacobelli, M.6
-
23
-
-
0031909016
-
Endothelial dysfunction after bone marrow transplantation: Increase of soluble thrombomodulin and PAI-1 in patients with multiple transplant-related complications
-
Nurnberger W, Michelmann I, Burdach S, Gobel U. Endothelial dysfunction after bone marrow transplantation: Increase of soluble thrombomodulin and PAI-1 in patients with multiple transplant-related complications. Ann Hematol 1998; 76: 61-65.
-
(1998)
Ann Hematol
, vol.76
, pp. 61-65
-
-
Nurnberger, W.1
Michelmann, I.2
Burdach, S.3
Gobel, U.4
-
24
-
-
0030933936
-
Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplant
-
Salat C, Holler E, Kolbe HJ, Brigitte R, Pihusch R, Wolfgang W et al Plasminogen activator inhibitor-1 confirms the diagnosis of hepatic veno-occlusive disease in patients with hyperbilirubinemia after bone marrow transplant. Blood 1997; 89: 2184-2188.
-
(1997)
Blood
, vol.89
, pp. 2184-2188
-
-
Salat, C.1
Holler, E.2
Kolbe, H.J.3
Brigitte, R.4
Pihusch, R.5
Wolfgang, W.6
-
25
-
-
18544367609
-
Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulphan and cyclophosphamide
-
Lee JH, Lee KH, Kim S, Seol M, Park CJ, Chi HS et al. Plasminogen activator inhibitor-1 is an independent diagnostic marker as well as severity predictor of hepatic veno-occlusive disease after allogeneic bone marrow transplantation in adults conditioned with busulphan and cyclophosphamide. Br J Haematol 2002; 118: 1087-1094.
-
(2002)
Br J Haematol
, vol.118
, pp. 1087-1094
-
-
Lee, J.H.1
Lee, K.H.2
Kim, S.3
Seol, M.4
Park, C.J.5
Chi, H.S.6
-
26
-
-
34249936326
-
The use of defibrotide (DF) in BMT-associated veno-occlusive disease (VOD) (Meeting abstract)
-
Richardson P, Krishnan A, Wheeler C, Fyfe H, Hoppensteadt D, Fareed J et al. The use of defibrotide (DF) in BMT-associated veno-occlusive disease (VOD) (Meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1996; 15: A13 1996.
-
(1996)
Proc Annu Meet Am Soc Clin Oncol
, vol.15
-
-
Richardson, P.1
Krishnan, A.2
Wheeler, C.3
Fyfe, H.4
Hoppensteadt, D.5
Fareed, J.6
-
27
-
-
20144366170
-
Transforming growth factor bota-1 released from platelets contributes to hypercoagulability in veno-occlusive disease following hematopoietic stem cell transplantation
-
Pihusch V, Pihusch M, Penovici M, Kolb HJ, Hiller E, Pihusch R. Transforming growth factor bota-1 released from platelets contributes to hypercoagulability in veno-occlusive disease following hematopoietic stem cell transplantation. Thromb Res 2005; 116: 233-240.
-
(2005)
Thromb Res
, vol.116
, pp. 233-240
-
-
Pihusch, V.1
Pihusch, M.2
Penovici, M.3
Kolb, H.J.4
Hiller, E.5
Pihusch, R.6
-
28
-
-
0027193827
-
Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer
-
Anscher MS, Peters WP, Reisenbichler H, Petros WP, Jirtle RL. Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N Engl J Med 1993; 328: 1592-1598.
-
(1993)
N Engl J Med
, vol.328
, pp. 1592-1598
-
-
Anscher, M.S.1
Peters, W.P.2
Reisenbichler, H.3
Petros, W.P.4
Jirtle, R.L.5
-
29
-
-
0141532294
-
Decreased hepatic nitric oxide production contributes to the development of rat sinusoidal obstruction syndrome
-
DeLeve LD, Wang X, Kanel GC, Ito Y, Bethea NW, McCuskey MK et al. Decreased hepatic nitric oxide production contributes to the development of rat sinusoidal obstruction syndrome. Hepatology 2003; 38: 900-908.
-
(2003)
Hepatology
, vol.38
, pp. 900-908
-
-
DeLeve, L.D.1
Wang, X.2
Kanel, G.C.3
Ito, Y.4
Bethea, N.W.5
McCuskey, M.K.6
-
30
-
-
3342965181
-
Effect of sodium nitroprusside on ischemia-reperfusion injuries of the rat liver
-
Kuroki I, Miyazaki T, Mizukami I, Matsumoto N, Matsumoto I. Effect of sodium nitroprusside on ischemia-reperfusion injuries of the rat liver. Repatogastroenterology 2004; 51: 1404-1407.
-
(2004)
Repatogastroenterology
, vol.51
, pp. 1404-1407
-
-
Kuroki, I.1
Miyazaki, T.2
Mizukami, I.3
Matsumoto, N.4
Matsumoto, I.5
-
31
-
-
30144437889
-
Pivotal role of PAI-1 in a murine model of hepatic vein thrombosis
-
Smith LH, Dixon JD, Stringham JR, Eren M, Elokdah H, Crandall DL et al. Pivotal role of PAI-1 in a murine model of hepatic vein thrombosis. Blood 2006; 107: 132-134.
-
(2006)
Blood
, vol.107
, pp. 132-134
-
-
Smith, L.H.1
Dixon, J.D.2
Stringham, J.R.3
Eren, M.4
Elokdah, H.5
Crandall, D.L.6
-
32
-
-
0036125693
-
Toxic injury to hepatic sinusoids: Sinusoidal obstruction syndrome (veno-occlusive disease)
-
DeLeve L, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002; 22: 27-42.
-
(2002)
Semin Liver Dis
, vol.22
, pp. 27-42
-
-
DeLeve, L.1
Shulman, H.M.2
McDonald, G.B.3
-
33
-
-
0038069155
-
Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation
-
Kumar S, DeLeve LD, Kamath PS, Tefferi A. Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation. Mayo Clin Proc 2003; 78: 589-598.
-
(2003)
Mayo Clin Proc
, vol.78
, pp. 589-598
-
-
Kumar, S.1
DeLeve, L.D.2
Kamath, P.S.3
Tefferi, A.4
-
34
-
-
0001980758
-
Venocclusive disease of the liver following marrow transplantation
-
McDonald GB. Venocclusive disease of the liver following marrow transplantation. Marrow Transplant Rev 1993; 3: 49-56.
-
(1993)
Marrow Transplant Rev
, vol.3
, pp. 49-56
-
-
McDonald, G.B.1
-
35
-
-
13344250481
-
Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia
-
Rozman C, Carreras E, Qian C, Gale RP, Bortin MM, Rowlings PA et al Risk factors for hepatic veno-occlusive disease following HLA-identical sibling bone marrow transplants for leukemia. Bone Marrow Transplant 1996; 17: 75-80.
-
(1996)
Bone Marrow Transplant
, vol.17
, pp. 75-80
-
-
Rozman, C.1
Carreras, E.2
Qian, C.3
Gale, R.P.4
Bortin, M.M.5
Rowlings, P.A.6
-
36
-
-
10744231461
-
Positive selection for CD34 reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation
-
Moscardo F, Urbano-Ispizua A, Sanz GF, Brunet S, Caballero D, Vallejo C et al. Positive selection for CD34 reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. Exp Hematol 2003; 31: 545-550.
-
(2003)
Exp Hematol
, vol.31
, pp. 545-550
-
-
Moscardo, F.1
Urbano-Ispizua, A.2
Sanz, G.F.3
Brunet, S.4
Caballero, D.5
Vallejo, C.6
-
37
-
-
0025780243
-
Regimen-related toxicity of a busulfancyclophosphamide conditioning regimen in 70 patients undergoing allogeneic bone marrow transplantation
-
Nevill TJ, Barnett MJ, Klingemann HG, Reece DE, Shepherd JD, Phillips GL. Regimen-related toxicity of a busulfancyclophosphamide conditioning regimen in 70 patients undergoing allogeneic bone marrow transplantation. J Clin Oncol 1991; 9: 1224-1232.
-
(1991)
J Clin Oncol
, vol.9
, pp. 1224-1232
-
-
Nevill, T.J.1
Barnett, M.J.2
Klingemann, H.G.3
Reece, D.E.4
Shepherd, J.D.5
Phillips, G.L.6
-
38
-
-
0031833915
-
Association of pulmonary function testing abnormalities and severe veno-occlusive disease of the liver after marrow transplantation
-
Matute-Bello G, McDonald GD, Hinds MS, Schoch HG, Crawford SW. Association of pulmonary function testing abnormalities and severe veno-occlusive disease of the liver after marrow transplantation. Bone Marrow Transplant 1998; 21: 1125-1130.
-
(1998)
Bone Marrow Transplant
, vol.21
, pp. 1125-1130
-
-
Matute-Bello, G.1
McDonald, G.D.2
Hinds, M.S.3
Schoch, H.G.4
Crawford, S.W.5
-
39
-
-
27144472703
-
A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation
-
Cesaro S, Pillon M, Talenti E, Toffolutti T, Calore E. Tridello G et al. A prospective survey on incidence, risk factors and therapy of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation. Haematologica 2005; 90: 1396-1404.
-
(2005)
Haematologica
, vol.90
, pp. 1396-1404
-
-
Cesaro, S.1
Pillon, M.2
Talenti, E.3
Toffolutti, T.4
Calore, E.5
Tridello, G.6
-
40
-
-
0028210717
-
A randomized trial comparing busulfan with total body irradiation as conditioning in aliogeneic marrow transplant recipients with leukemia: A report from the Nordic Bone Marrow Transplantation Group
-
Ringden O, Ruutu T, Remberger M, Nikoskelainer L, Volin L, Vindelov T et al. A randomized trial comparing busulfan with total body irradiation as conditioning in aliogeneic marrow transplant recipients with leukemia: A report from the Nordic Bone Marrow Transplantation Group. Blood 1994; 83: 2723-2730.
-
(1994)
Blood
, vol.83
, pp. 2723-2730
-
-
Ringden, O.1
Ruutu, T.2
Remberger, M.3
Nikoskelainer, L.4
Volin, L.5
Vindelov, T.6
-
41
-
-
0034960016
-
Busulfan levels are influenced by prior treatment and are associated with hepatic veno occiusive disease and early mortality but not with delayed complications following marrow transplantation
-
Copelan EA, Bechtel TP, Avalos BR, Elder PJ, Ezzone SA, Scholl MD et al. Busulfan levels are influenced by prior treatment and are associated with hepatic veno occiusive disease and early mortality but not with delayed complications following marrow transplantation. Bone Marrow Transplant 2001; 27: 1121-1124.
-
(2001)
Bone Marrow Transplant
, vol.27
, pp. 1121-1124
-
-
Copelan, E.A.1
Bechtel, T.P.2
Avalos, B.R.3
Elder, P.J.4
Ezzone, S.A.5
Scholl, M.D.6
-
42
-
-
0037370735
-
Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoistic stem cell transplantation
-
McDonald GB, Slattery JT, Bouvier ME, Ren S, Batchelder AL, Kalhorn TF et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoistic stem cell transplantation. Blood 2003; 101: 2043-2048.
-
(2003)
Blood
, vol.101
, pp. 2043-2048
-
-
McDonald, G.B.1
Slattery, J.T.2
Bouvier, M.E.3
Ren, S.4
Batchelder, A.L.5
Kalhorn, T.F.6
-
43
-
-
23244433213
-
Decreased incidence of hepatic NDeno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan+cyclophosphamide for allogeneic bone marrow transplantation
-
Lee JH, Choi SJ, Kim SE, Park CJ, Chi HS, Lee MS et al. Decreased incidence of hepatic NDeno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan+cyclophosphamide for allogeneic bone marrow transplantation. Ann Hematol 2005; 84: 321-330.
-
(2005)
Ann Hematol
, vol.84
, pp. 321-330
-
-
Lee, J.H.1
Choi, S.J.2
Kim, S.E.3
Park, C.J.4
Chi, H.S.5
Lee, M.S.6
-
44
-
-
33745011812
-
Absence of veno-occlusive disease in a cohort of multiple myeloma patients undergoing autologous stem cell transplantasion with targeted busulfan dosage
-
Clopes A, Sureda A, Sierra J, Queralto JM, Broto A, Farre R et al. Absence of veno-occlusive disease in a cohort of multiple myeloma patients undergoing autologous stem cell transplantasion with targeted busulfan dosage. Eur J Haematol 2006; 77: 1-6.
-
(2006)
Eur J Haematol
, vol.77
, pp. 1-6
-
-
Clopes, A.1
Sureda, A.2
Sierra, J.3
Queralto, J.M.4
Broto, A.5
Farre, R.6
-
45
-
-
34250206633
-
Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: Pharmacokinetics, liver toxicity, and mortality
-
McCune JS, Batchelder A, Deeg HJ, Gooley T, Cole S, Phillips B et al Cyclophosphamide following targeted oral busulfan as conditioning for hematopoietic cell transplantation: Pharmacokinetics, liver toxicity, and mortality. Biol Blood Marrow Transplant 2007; 13 853-862.
-
(2007)
Biol Blood Marrow Transplant
, vol.13
, pp. 853-862
-
-
McCune, J.S.1
Batchelder, A.2
Deeg, H.J.3
Gooley, T.4
Cole, S.5
Phillips, B.6
-
46
-
-
0042442407
-
Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation
-
Wadleigh M, Richardson PG, Zahrieh D, Lee SJ, Cutler C, Ho V et al Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 2003; 102: 1578-1582.
-
(2003)
Blood
, vol.102
, pp. 1578-1582
-
-
Wadleigh, M.1
Richardson, P.G.2
Zahrieh, D.3
Lee, S.J.4
Cutler, C.5
Ho, V.6
-
47
-
-
23744511263
-
Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33 + acute myeloid leukemia
-
Arceci RJ, Sande J, Lange B, Shannon K, Franklin J, Hutchinson R et al. Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33 + acute myeloid leukemia. Blood 2005; 106: 1183-1188.
-
(2005)
Blood
, vol.106
, pp. 1183-1188
-
-
Arceci, R.J.1
Sande, J.2
Lange, B.3
Shannon, K.4
Franklin, J.5
Hutchinson, R.6
-
48
-
-
34147197520
-
Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): An over-view from the research on adverse drug events and reports (RADAR) project
-
E-pub 7 September
-
McKoy JM, Angelotta C, Bennett CL, Tallman MS, Wadleigh M, Evens AM et al. Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): An over-view from the research on adverse drug events and reports (RADAR) project. Leuk Res 2007; 31: 599-604. E-pub 7 September 2006.
-
(2006)
Leuk Res 2007
, vol.31
, pp. 599-604
-
-
McKoy, J.M.1
Angelotta, C.2
Bennett, C.L.3
Tallman, M.S.4
Wadleigh, M.5
Evens, A.M.6
-
49
-
-
0026347036
-
Hepatic dysfunction following T-cell-depleted allogeneic bone marrow transplantation
-
Soiffer RJ, Dear K, Rabinowe SN, Anderson KC, Freedman AS, Murray C et al. Hepatic dysfunction following T-cell-depleted allogeneic bone marrow transplantation. Transplantation 1991; 52: 1014-1019.
-
(1991)
Transplantation
, vol.52
, pp. 1014-1019
-
-
Soiffer, R.J.1
Dear, K.2
Rabinowe, S.N.3
Anderson, K.C.4
Freedman, A.S.5
Murray, C.6
-
50
-
-
0034986714
-
Marked reduction in the incidence of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation with CD34(+) positive selection
-
Moscardo F, Sanz GF, de La Rubia J, Jimenez C, Saavedra S, Regadera A et al. Marked reduction in the incidence of hepatic veno-occlusive disease after allogeneic hematopoietic stem cell transplantation with CD34(+) positive selection. Bone Marrow Transplant 2001; 27: 983-988.
-
(2001)
Bone Marrow Transplant
, vol.27
, pp. 983-988
-
-
Moscardo, F.1
Sanz, G.F.2
de La Rubia, J.3
Jimenez, C.4
Saavedra, S.5
Regadera, A.6
-
51
-
-
10744231461
-
Positive selection for CD34+ reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation
-
Moscardo F, Urbano-Ispizua A, Sanz GF, Brunet S, Caballero D, Vallejo C et al. Positive selection for CD34+ reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. Exp Hematol 2003; 31: 545-550.
-
(2003)
Exp Hematol
, vol.31
, pp. 545-550
-
-
Moscardo, F.1
Urbano-Ispizua, A.2
Sanz, G.F.3
Brunet, S.4
Caballero, D.5
Vallejo, C.6
-
52
-
-
0041941520
-
Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation
-
Antin JH, Kim HT, Cutler C, Ho VT, Lee SJ, Miklos DB et al. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood 2003; 102: 1601-1605.
-
(2003)
Blood
, vol.102
, pp. 1601-1605
-
-
Antin, J.H.1
Kim, H.T.2
Cutler, C.3
Ho, V.T.4
Lee, S.J.5
Miklos, D.B.6
-
53
-
-
20844456461
-
Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation
-
Cutler C, Henry NL, Magee C, Li S, Kim HT, Alyea E et al. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005; 11: 551-557.
-
(2005)
Biol Blood Marrow Transplant
, vol.11
, pp. 551-557
-
-
Cutler, C.1
Henry, N.L.2
Magee, C.3
Li, S.4
Kim, H.T.5
Alyea, E.6
-
54
-
-
0036659926
-
Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: Protective effect of defibrotide
-
Eissner G, Multhoff G, Gerbitz A, Kirchner S, Bauer S, Haffner S et al. Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: Protective effect of defibrotide. Blood 2002; 100: 334-340.
-
(2002)
Blood
, vol.100
, pp. 334-340
-
-
Eissner, G.1
Multhoff, G.2
Gerbitz, A.3
Kirchner, S.4
Bauer, S.5
Haffner, S.6
-
55
-
-
0027259024
-
Defibrotide, a single-stranded polydeoxyribonucleotide acting as an adenosine receptor agonist
-
Bianchi G, Barone D, Lanzarotti E, Tettamanti R, Porta R, Moltrasio D et al. Defibrotide, a single-stranded polydeoxyribonucleotide acting as an adenosine receptor agonist. Eur J Pharmacol 1993; 238: 327-334.
-
(1993)
Eur J Pharmacol
, vol.238
, pp. 327-334
-
-
Bianchi, G.1
Barone, D.2
Lanzarotti, E.3
Tettamanti, R.4
Porta, R.5
Moltrasio, D.6
-
56
-
-
0028347781
-
Isolation and identification of aptamers from defibrotide that act as thrombin antagonists in vitro
-
Bracht F, Schror K. Isolation and identification of aptamers from defibrotide that act as thrombin antagonists in vitro. Biochem Biophys Res Commun 1994; 200: 933-936.
-
(1994)
Biochem Biophys Res Commun
, vol.200
, pp. 933-936
-
-
Bracht, F.1
Schror, K.2
-
57
-
-
0023800090
-
Acute effects of defibrotide, an experimental antithrombotic agent, on fibrinolysis and blood prostanoids in man
-
Coccheri S, Biagi G, Legnani C, Bianchini B, Grauso F. Acute effects of defibrotide, an experimental antithrombotic agent, on fibrinolysis and blood prostanoids in man. Eur J Clin Pharmacol 1988; 35: 151-156.
-
(1988)
Eur J Clin Pharmacol
, vol.35
, pp. 151-156
-
-
Coccheri, S.1
Biagi, G.2
Legnani, C.3
Bianchini, B.4
Grauso, F.5
-
58
-
-
0025001566
-
Defibrotide by enhancing prostacyclin generation prevents endothelin-I induced contraction in human saphenous veins
-
Berti F, Rossoni G, Biasi G, Buschi A, Mandelli V. Defibrotide by enhancing prostacyclin generation prevents endothelin-I induced contraction in human saphenous veins. Prostaglandins 1990; 40 337-350.
-
(1990)
Prostaglandins
, vol.40
, pp. 337-350
-
-
Berti, F.1
Rossoni, G.2
Biasi, G.3
Buschi, A.4
Mandelli, V.5
-
59
-
-
0028199746
-
Defibrotide stimulates expression of thrombomodulin in human endothelial cells
-
Zhou Q, Chu X, Ruan C. Defibrotide stimulates expression of thrombomodulin in human endothelial cells. Thromb Hemost 1994; 71: 507-510.
-
(1994)
Thromb Hemost
, vol.71
, pp. 507-510
-
-
Zhou, Q.1
Chu, X.2
Ruan, C.3
-
60
-
-
0003288420
-
Modulation of endothelium by heparins and defibrotide
-
Nicolaides A, Novo S eds, Elsevier Science B.V, Amsterdam
-
Fareed J. Modulation of endothelium by heparins and defibrotide. In: Nicolaides A, Novo S (eds). Advances in Vascular Pathology 1997. Elsevier Science B.V.: Amsterdam, 1997, pp 25-32.
-
(1997)
Advances in Vascular Pathology 1997
, pp. 25-32
-
-
Fareed, J.1
-
61
-
-
0027258661
-
Antithrombotic effect and clinical potential of defibrotide
-
Ulutin ON. Antithrombotic effect and clinical potential of defibrotide. Sem Thromb Hemost 1993, 19: 186-191.
-
(1993)
Sem Thromb Hemost
, vol.19
, pp. 186-191
-
-
Ulutin, O.N.1
-
62
-
-
0029866306
-
The action of polyanionic agents defibrotide and pentosan sulphate on fibrinolytic activity in the laboratory rat
-
Jamieson A, Alcock P, Tuffin DP. The action of polyanionic agents defibrotide and pentosan sulphate on fibrinolytic activity in the laboratory rat. Fibrinolysis 1996; 10: 27-35.
-
(1996)
Fibrinolysis
, vol.10
, pp. 27-35
-
-
Jamieson, A.1
Alcock, P.2
Tuffin, D.P.3
-
63
-
-
0003296788
-
Defibrotide (DF) modulates tissue factor expression by microvascular endothelial cells
-
Falanga A, Marchetti M, Vignoli A, Barbui T. Defibrotide (DF) modulates tissue factor expression by microvascular endothelial cells. Blood 1999; 94: 146a.
-
(1999)
Blood
, vol.94
-
-
Falanga, A.1
Marchetti, M.2
Vignoli, A.3
Barbui, T.4
-
64
-
-
85112366465
-
Impact of defibrotide on the fibrinolytic and procoagulant properties of endothelial cell macro- and micro-vessels
-
Falanga A, Marchetti M, Vignoli A, Barbui T. Impact of defibrotide on the fibrinolytic and procoagulant properties of endothelial cell macro- and micro-vessels. Blood 2000; 96: 53a.
-
(2000)
Blood
, vol.96
-
-
Falanga, A.1
Marchetti, M.2
Vignoli, A.3
Barbui, T.4
-
65
-
-
0032147122
-
Treatment of severe veno-occlusive disease with defibrotide: Compassionate use results in response without significant toxicity in a high-risk population
-
Richardson PG, Elias AD, Krishnan A, Wheeler C, Nath R, Hoppensteadt D et al. Treatment of severe veno-occlusive disease with defibrotide: Compassionate use results in response without significant toxicity in a high-risk population. Blood 1998; 92: 737-744.
-
(1998)
Blood
, vol.92
, pp. 737-744
-
-
Richardson, P.G.1
Elias, A.D.2
Krishnan, A.3
Wheeler, C.4
Nath, R.5
Hoppensteadt, D.6
-
66
-
-
0037114746
-
Multi-institutional use of defibrotide in 88 patients post stem cell transplant with severe veno-occlusive disease and multi-system organ failure; response without significant toxicity in a high risk population and factors predictive of outcome
-
Richardson P, Murakami C, Jin Z, Warren D, Momtaz P, Hoppensteadt DA et al. Multi-institutional use of defibrotide in 88 patients post stem cell transplant with severe veno-occlusive disease and multi-system organ failure; response without significant toxicity in a high risk population and factors predictive of outcome. Blood 2002; 100 4337-4343.
-
(2002)
Blood
, vol.100
, pp. 4337-4343
-
-
Richardson, P.1
Murakami, C.2
Jin, Z.3
Warren, D.4
Momtaz, P.5
Hoppensteadt, D.A.6
-
67
-
-
34248187052
-
Defibrotide for the treatment of hepatic veno-occlusive disease in children
-
Bulley SR, Strahm B, Doyle J, Dupuis LL. Defibrotide for the treatment of hepatic veno-occlusive disease in children. Pediatr Blood Cancer 2007; 48: 700-704.
-
(2007)
Pediatr Blood Cancer
, vol.48
, pp. 700-704
-
-
Bulley, S.R.1
Strahm, B.2
Doyle, J.3
Dupuis, L.L.4
-
68
-
-
39349084973
-
Defibrotide (DF) for the treatment of severe veno-occlusive disease (sVOD) and multi-organ failure (MOF) post SCT: Final results of a multi-center, randomized, dose-finding trial
-
Richardson P. Soiffer R, Antin J, Jin Z, Kurtzberg J, Martin P et al Defibrotide (DF) for the treatment of severe veno-occlusive disease (sVOD) and multi-organ failure (MOF) post SCT: Final results of a multi-center, randomized, dose-finding trial. Blood 2006; 108 178.
-
(2006)
Blood
, vol.108
, pp. 178
-
-
Richardson, P.1
Soiffer, R.2
Antin, J.3
Jin, Z.4
Kurtzberg, J.5
Martin, P.6
-
69
-
-
0022873295
-
Effects of defibrotide in acute renal failure due to thrombotic microangiopathy
-
Vangelista A, Frasca GM, Raimondi C, Liviano-D'Arcangelo G, Bonomini V. Effects of defibrotide in acute renal failure due to thrombotic microangiopathy. Haemostasis 1986; 16 (Suppl 1): 51-54.
-
(1986)
Haemostasis
, vol.16
, Issue.SUPPL. 1
, pp. 51-54
-
-
Vangelista, A.1
Frasca, G.M.2
Raimondi, C.3
Liviano-D'Arcangelo, G.4
Bonomini, V.5
-
70
-
-
0027236877
-
Venoocclusive disease of the liver: Development of a model for predicting fatal outcome after marrov transplantation
-
Bearman SI, Anderson GL, Mori M, Hinds MS, Shulman HM, McDonald GB. Venoocclusive disease of the liver: Development of a model for predicting fatal outcome after marrov transplantation. J Clin Oncol 1993; 11: 1729-1736.
-
(1993)
J Clin Oncol
, vol.11
, pp. 1729-1736
-
-
Bearman, S.I.1
Anderson, G.L.2
Mori, M.3
Hinds, M.S.4
Shulman, H.M.5
McDonald, G.B.6
-
71
-
-
85117737565
-
Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure
-
letter to editor
-
Versluys B, Bhattacharaya R, Steward C, Cornish J, Oakhill A, Goulden N. Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure. Blood 2004; 103: 1968; letter to editor.
-
(1968)
Blood 2004
, vol.103
-
-
Versluys, B.1
Bhattacharaya, R.2
Steward, C.3
Cornish, J.4
Oakhill, A.5
Goulden, N.6
-
72
-
-
0025044352
-
Veno-occlusive disease of the liver complicating ABMT successfully treated with recombinant tissue plasminogen activator (rt-PA)
-
Baglin TP, Harper P, Marcus RE. Veno-occlusive disease of the liver complicating ABMT successfully treated with recombinant tissue plasminogen activator (rt-PA). Bone Marrow Transplant 1990; 5 439-441.
-
(1990)
Bone Marrow Transplant
, vol.5
, pp. 439-441
-
-
Baglin, T.P.1
Harper, P.2
Marcus, R.E.3
-
73
-
-
1842336845
-
Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients
-
Bearman SI, Lee JL, Baron AE, McDonald GB. Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood 1997; 89 1501-1506.
-
(1997)
Blood
, vol.89
, pp. 1501-1506
-
-
Bearman, S.I.1
Lee, J.L.2
Baron, A.E.3
McDonald, G.B.4
-
74
-
-
0026606743
-
Alteplase for hepatic veno-occlusive disease complicating bone-marrow transplantation [letter] [see comments]
-
Laporte JP, Lesage S, Tilleul P, Najman A, Gorin NC. Alteplase for hepatic veno-occlusive disease complicating bone-marrow transplantation [letter] [see comments]. Lancet 1992; 339: 1057.
-
(1992)
Lancet
, vol.339
, pp. 1057
-
-
Laporte, J.P.1
Lesage, S.2
Tilleul, P.3
Najman, A.4
Gorin, N.C.5
-
75
-
-
0026723814
-
Alteplase for hepatic veno-occlusive disease after bone-marrow transplantation [letter; comment] [see comments]
-
Rosti G, Bandini G, Belardinelli A, Calod E, Tura S, Gherlinzoni F et al. Alteplase for hepatic veno-occlusive disease after bone-marrow transplantation [letter; comment] [see comments]. Lancet 1992; 339: 1481-1482.
-
(1992)
Lancet
, vol.339
, pp. 1481-1482
-
-
Rosti, G.1
Bandini, G.2
Belardinelli, A.3
Calod, E.4
Tura, S.5
Gherlinzoni, F.6
-
76
-
-
0026795936
-
Alteplase for hepatic veno-occlusive disease after bone marrow transplantation [letter; comment]
-
Ringden O, Wennberg L, Ericzon BG, Kallman R, Astrom M, Duraj F et al Alteplase for hepatic veno-occlusive disease after bone marrow transplantation [letter; comment]. Lancet 1992; 340: 546-547.
-
(1992)
Lancet
, vol.340
, pp. 546-547
-
-
Ringden, O.1
Wennberg, L.2
Ericzon, B.G.3
Kallman, R.4
Astrom, M.5
Duraj, F.6
-
77
-
-
0030037141
-
Recombinant human tissue plasminogen activator for the treatment of severe hepatic veno-occlusive disease in pediatric bone marrow transplant patients
-
Leahey AM, Bunin NJ. Recombinant human tissue plasminogen activator for the treatment of severe hepatic veno-occlusive disease in pediatric bone marrow transplant patients. Bone Marrow Transplant 1996; 17: 1101-1104.
-
(1996)
Bone Marrow Transplant
, vol.17
, pp. 1101-1104
-
-
Leahey, A.M.1
Bunin, N.J.2
-
79
-
-
0029792765
-
Treatment of hepatic veno-occlusive disease with low-dose tissue plasminogen activator: Impact on coagulation profile
-
Goldberg SL, Shubert J, Rao AK, Redei I, Klumpp TR, Mangan KF. Treatment of hepatic veno-occlusive disease with low-dose tissue plasminogen activator: Impact on coagulation profile. Bone Marrow Transplant 1996; 18: 633-636.
-
(1996)
Bone Marrow Transplant
, vol.18
, pp. 633-636
-
-
Goldberg, S.L.1
Shubert, J.2
Rao, A.K.3
Redei, I.4
Klumpp, T.R.5
Mangan, K.F.6
-
80
-
-
0029068719
-
Successful treatment of an infant with veno-occlusive disease developed after allogeneic bone marrow transplantation by tissue plasminogen activator, heparin and prostaglandin E1
-
Higashigawa M, Watanabe M, Nishihara H, Tabata N, Azuma, E, Ido M et al. Successful treatment of an infant with veno-occlusive disease developed after allogeneic bone marrow transplantation by tissue plasminogen activator, heparin and prostaglandin E1. Leuk Res 1995; 19: 477-480.
-
(1995)
Leuk Res
, vol.19
, pp. 477-480
-
-
Higashigawa, M.1
Watanabe, M.2
Nishihara, H.3
Tabata, N.4
Azuma, E.5
Ido, M.6
-
81
-
-
0029587501
-
No beneficial effects, but severe side effects caused by recombinant human tissue plasminogen activator for treatment of hepatic veno-occlusive disease after allogeneic bone marrow transplantation
-
Hagglund H, Ringden O, Ljungman P. No beneficial effects, but severe side effects caused by recombinant human tissue plasminogen activator for treatment of hepatic veno-occlusive disease after allogeneic bone marrow transplantation. Transplantation 1995; 27: 3535.
-
(1995)
Transplantation
, vol.27
, pp. 3535
-
-
Hagglund, H.1
Ringden, O.2
Ljungman, P.3
-
82
-
-
0030113020
-
Veno-occlusive disease (VOD) of the liver in Korean patients following allogeneic bone marrow transplantation (BMT): Efficacy of recombinant human tissue plasminogen activator (rt-PA) treatment
-
Lee JH, Lee KH, Choi JS, Zang DY, Kim SB, Kim SW et al. Veno-occlusive disease (VOD) of the liver in Korean patients following allogeneic bone marrow transplantation (BMT): Efficacy of recombinant human tissue plasminogen activator (rt-PA) treatment. J Korean Med Sci 1996; 11: 118-126.
-
(1996)
J Korean Med Sci
, vol.11
, pp. 118-126
-
-
Lee, J.H.1
Lee, K.H.2
Choi, J.S.3
Zang, D.Y.4
Kim, S.B.5
Kim, S.W.6
-
83
-
-
0028228501
-
Recombinant tissue plasminogen activator (rt-PA) for veno-occlusive liver disease in pediatric autologous bone marrow transplant patients
-
Yu LC, Malkani I, Regueira O, Ode DL, Warrier RP. Recombinant tissue plasminogen activator (rt-PA) for veno-occlusive liver disease in pediatric autologous bone marrow transplant patients. Am J Hematol 1994; 46: 194-198.
-
(1994)
Am J Hematol
, vol.46
, pp. 194-198
-
-
Yu, L.C.1
Malkani, I.2
Regueira, O.3
Ode, D.L.4
Warrier, R.P.5
-
84
-
-
0033374251
-
Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation
-
Schriber J, Milk B, Shaw D, Christiansen N, Baer M, Slack J et al. Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation. Bone Marrow Transplant 1999; 24: 1311-1314.
-
(1999)
Bone Marrow Transplant
, vol.24
, pp. 1311-1314
-
-
Schriber, J.1
Milk, B.2
Shaw, D.3
Christiansen, N.4
Baer, M.5
Slack, J.6
-
85
-
-
0032891890
-
Recombinant tissue plasminogen activator (rtPA) for the treatment of hepatic veno-occlusive disease (VOD)
-
Kulkarni S, Rodriguez M, Lafuente A, Mateos P, Mehta J, Singhal S et al. Recombinant tissue plasminogen activator (rtPA) for the treatment of hepatic veno-occlusive disease (VOD). Bone Marrow Transplant 1999; 23: 803-807.
-
(1999)
Bone Marrow Transplant
, vol.23
, pp. 803-807
-
-
Kulkarni, S.1
Rodriguez, M.2
Lafuente, A.3
Mateos, P.4
Mehta, J.5
Singhal, S.6
-
86
-
-
0030864269
-
-
Morris JD, Harris RE, Hashmi R, Sambrano JE, Gruppo RA, Becker AT et al. Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation. Bone Marrow Transplant 1997; 20: 871-878.
-
Morris JD, Harris RE, Hashmi R, Sambrano JE, Gruppo RA, Becker AT et al. Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation. Bone Marrow Transplant 1997; 20: 871-878.
-
-
-
-
87
-
-
0033373299
-
Antithrombin treatment of severe hepatic veno-occlusive disease in children with cancer
-
Mertens R, Brost H, Granzen B, Nowak-Gottl U. Antithrombin treatment of severe hepatic veno-occlusive disease in children with cancer. Eur J Pediatr 1999; 158 (Suppl 3): S154-S158.
-
(1999)
Eur J Pediatr
, vol.158
, Issue.SUPPL. 3
-
-
Mertens, R.1
Brost, H.2
Granzen, B.3
Nowak-Gottl, U.4
-
88
-
-
2442670748
-
Anti-thrombin III in the management of hematopoietic stem-cell transplantation-associated toxicity
-
Ibrahim RB, Peres E, Dansey R, Abidi MH, Abella EM, Klein J. Anti-thrombin III in the management of hematopoietic stem-cell transplantation-associated toxicity. Ann Pharmacother 2004; 38 1053-1059.
-
(2004)
Ann Pharmacother
, vol.38
, pp. 1053-1059
-
-
Ibrahim, R.B.1
Peres, E.2
Dansey, R.3
Abidi, M.H.4
Abella, E.M.5
Klein, J.6
-
89
-
-
33745751942
-
Hepatic veno-occlusive disease in pediatric stem cell transplantation: Impact of pre-emptive antithrombin III replacement and combined antithrombin III/ denbrotide therapy
-
Haussmann U, Fischer J, Eber S, Scherer F, Seger R, Gungor T. Hepatic veno-occlusive disease in pediatric stem cell transplantation: Impact of pre-emptive antithrombin III replacement and combined antithrombin III/ denbrotide therapy. Haematologica 2006; 91: 795-800.
-
(2006)
Haematologica
, vol.91
, pp. 795-800
-
-
Haussmann, U.1
Fischer, J.2
Eber, S.3
Scherer, F.4
Seger, R.5
Gungor, T.6
-
90
-
-
0024477970
-
PGE1 accelerates thrombolysis by tissue plasminogen activator
-
Vaughan DE, Plavin SR, Schafer AI, Loscalzo J. PGE1 accelerates thrombolysis by tissue plasminogen activator. Blood 1989; 73 1213-1217.
-
(1989)
Blood
, vol.73
, pp. 1213-1217
-
-
Vaughan, D.E.1
Plavin, S.R.2
Schafer, A.I.3
Loscalzo, J.4
-
91
-
-
0031965306
-
Hepatic veno-occlusive disease in pediatric stem cell recipients: Successful treatment with continuous infusion of prostaglandin El and low-dose heparin
-
Schlegel PG, Haber HP, Beck J, Krumpelmann S, Handgretinger R, Bader P et al. Hepatic veno-occlusive disease in pediatric stem cell recipients: Successful treatment with continuous infusion of prostaglandin El and low-dose heparin. Ann Hematol 1998; 76: 37-41.
-
(1998)
Ann Hematol
, vol.76
, pp. 37-41
-
-
Schlegel, P.G.1
Haber, H.P.2
Beck, J.3
Krumpelmann, S.4
Handgretinger, R.5
Bader, P.6
-
92
-
-
0027326608
-
A phase I/II study of prostaglandin E1 for the prevention of hepatic venocclusive disease after bone marrow transplantation
-
Bearman SI, Shen DD, Hinds MS, Hill HA, McDonald GB. A phase I/II study of prostaglandin E1 for the prevention of hepatic venocclusive disease after bone marrow transplantation. Br J Haematol 1993; 84: 724-730.
-
(1993)
Br J Haematol
, vol.84
, pp. 724-730
-
-
Bearman, S.I.1
Shen, D.D.2
Hinds, M.S.3
Hill, H.A.4
McDonald, G.B.5
-
93
-
-
0026720385
-
Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: A prospective, randomized trial
-
Attal M, Huguet F, Rubie H, Huynh A, Charlet JP, Payen JL et al. Prevention of hepatic veno-occlusive disease after bone marrow transplantation by continuous infusion of low-dose heparin: A prospective, randomized trial. Blood 1992; 79: 2834-2840.
-
(1992)
Blood
, vol.79
, pp. 2834-2840
-
-
Attal, M.1
Huguet, F.2
Rubie, H.3
Huynh, A.4
Charlet, J.P.5
Payen, J.L.6
-
94
-
-
0025016567
-
A pilot study of continuous infusion heparin for the prevention of hepatic veno-occlusive disease after bone marrow transplantation
-
Bearman SI, Hinds MS, Wolford JL, Petersen FB, Nugent DL, Slichter SJ et al. A pilot study of continuous infusion heparin for the prevention of hepatic veno-occlusive disease after bone marrow transplantation. Bone Marrow Transplant 1990; 5: 407-411.
-
(1990)
Bone Marrow Transplant
, vol.5
, pp. 407-411
-
-
Bearman, S.I.1
Hinds, M.S.2
Wolford, J.L.3
Petersen, F.B.4
Nugent, D.L.5
Slichter, S.J.6
-
95
-
-
0026348257
-
Prophylactic heparin does not prevent liver veno-occclusive disease following autologous bone marrow transplantation
-
Marsa-Vila L, Gorin NC, Laporte JP. Prophylactic heparin does not prevent liver veno-occclusive disease following autologous bone marrow transplantation. Eur J Haematol 1991; 47: 346-352.
-
(1991)
Eur J Haematol
, vol.47
, pp. 346-352
-
-
Marsa-Vila, L.1
Gorin, N.C.2
Laporte, J.P.3
-
96
-
-
9244265492
-
Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients
-
Or R, Nagler A, Shpilberg O, Elad S, Naparstek E, Kapelushnik J et al Low molecular weight heparin for the prevention of veno-occlusive disease of the liver in bone marrow transplantation patients. Transplantation 1996; 61: 1067-1071.
-
(1996)
Transplantation
, vol.61
, pp. 1067-1071
-
-
Or, R.1
Nagler, A.2
Shpilberg, O.3
Elad, S.4
Naparstek, E.5
Kapelushnik, J.6
-
97
-
-
17744388789
-
Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: Possible beneficial use of low molecular weight heparin
-
Simon M, Hahn T, Ford LA, Anderson B, Swinnich D, Baer MR et al. Retrospective multivariate analysis of hepatic veno-occlusive disease after blood or marrow transplantation: Possible beneficial use of low molecular weight heparin. Bone Marrow Transplant 2001; 27: 627-633.
-
(2001)
Bone Marrow Transplant
, vol.27
, pp. 627-633
-
-
Simon, M.1
Hahn, T.2
Ford, L.A.3
Anderson, B.4
Swinnich, D.5
Baer, M.R.6
-
98
-
-
85047696457
-
A randomized trial of heparin plus ursodiol vs heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation
-
Park SH, Lee MH, Lee H, Kim HS, Kim K, Kim WS et al. A randomized trial of heparin plus ursodiol vs heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29: 137-143.
-
(2002)
Bone Marrow Transplant
, vol.29
, pp. 137-143
-
-
Park, S.H.1
Lee, M.H.2
Lee, H.3
Kim, H.S.4
Kim, K.5
Kim, W.S.6
-
99
-
-
0037765452
-
Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: A prospective phase II study
-
Forrest DL, Thompson K, Dorcas VG, Couban SH, Pierce R. Low molecular weight heparin for the prevention of hepatic veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: A prospective phase II study. Bone Marrow Transplant 2003; 31: 1143-1149.
-
(2003)
Bone Marrow Transplant
, vol.31
, pp. 1143-1149
-
-
Forrest, D.L.1
Thompson, K.2
Dorcas, V.G.3
Couban, S.H.4
Pierce, R.5
-
100
-
-
0037765452
-
Low molecular weight heparin for the prevention of veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: A prospective phase II study
-
Forrest DL, Thompson K, Dorcas VG, Couban SH, Pierce R. Low molecular weight heparin for the prevention of veno-occlusive disease (VOD) after hematopoietic stem cell transplantation: A prospective phase II study Bone Marrow Transplant 2003; 31: 1143-1149.
-
(2003)
Bone Marrow Transplant
, vol.31
, pp. 1143-1149
-
-
Forrest, D.L.1
Thompson, K.2
Dorcas, V.G.3
Couban, S.H.4
Pierce, R.5
-
101
-
-
0034093330
-
The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veuo-occlusive disease after stem cell transplantation
-
Ohashi K, Tanabe J, Watanabe R, Tanaka T, Sakamaki H, Maruta A et al The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veuo-occlusive disease after stem cell transplantation. Am J Hematol 2000; 64: 32-38.
-
(2000)
Am J Hematol
, vol.64
, pp. 32-38
-
-
Ohashi, K.1
Tanabe, J.2
Watanabe, R.3
Tanaka, T.4
Sakamaki, H.5
Maruta, A.6
-
102
-
-
0026779860
-
Pilot trial of prophylactic ursodiol to decrease the incidence of veno-occlusive disease of the liver in allogeneic bone marrow transplant patients
-
Essell JH, Thompson JM, Harman GS, Halvorson RD, Snyder MJ, Callander NS et al. Pilot trial of prophylactic ursodiol to decrease the incidence of veno-occlusive disease of the liver in allogeneic bone marrow transplant patients. Bone Marrow Transplant 1992; 10: 367-372.
-
(1992)
Bone Marrow Transplant
, vol.10
, pp. 367-372
-
-
Essell, J.H.1
Thompson, J.M.2
Harman, G.S.3
Halvorson, R.D.4
Snyder, M.J.5
Callander, N.S.6
-
103
-
-
17344386370
-
Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial
-
Essell JH, Schroeder MT, Harman GS, Halvorson R, Lew V, Callander N et al. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128 (12 Part 1): 975-981.
-
(1998)
Ann Intern Med
, vol.128
, Issue.12 PART 1
, pp. 975-981
-
-
Essell, J.H.1
Schroeder, M.T.2
Harman, G.S.3
Halvorson, R.4
Lew, V.5
Callander, N.6
-
104
-
-
0037105367
-
Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation
-
Ruutu T, Eriksson B, Remes K, Juvonen E, Volin L, Remberger M et al Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002; 100: 1977-1983.
-
(2002)
Blood
, vol.100
, pp. 1977-1983
-
-
Ruutu, T.1
Eriksson, B.2
Remes, K.3
Juvonen, E.4
Volin, L.5
Remberger, M.6
-
105
-
-
0029154790
-
Allogeneic liver transplantation for hepatic veno-occlusive disease after bone marrow transplantation - clinical and immunological considerations
-
Schlitt HJ, Tischler HJ, Ringe B. Raddatz G, Maschek H, Dietrich H et al. Allogeneic liver transplantation for hepatic veno-occlusive disease after bone marrow transplantation - clinical and immunological considerations. Bone Marrow Transplant 1995; 16: 473-478.
-
(1995)
Bone Marrow Transplant
, vol.16
, pp. 473-478
-
-
Schlitt, H.J.1
Tischler, H.J.2
Ringe, B.3
Raddatz, G.4
Maschek, H.5
Dietrich, H.6
-
106
-
-
10144227048
-
Transjugular intrahepatic portosystemic shunting (TIPS) for the treatment of severe hepatic veno-occlusive disease
-
Smith FO, Johnson MS, Scherer LR et al. Transjugular intrahepatic portosystemic shunting (TIPS) for the treatment of severe hepatic veno-occlusive disease. Bone Marrow Transplant 1996; 18: 643-646.
-
(1996)
Bone Marrow Transplant
, vol.18
, pp. 643-646
-
-
Smith, F.O.1
Johnson, M.S.2
Scherer, L.R.3
-
107
-
-
0034171210
-
Percutaneous intrahepatic portosystemic shunting in the treatment of veno-occlusive disease of the liver after bone marrow transplantation
-
Alvarez R, Banares R, Casariego J, Echenagusia A, Simo G, Alvarez E et al. Percutaneous intrahepatic portosystemic shunting in the treatment of veno-occlusive disease of the liver after bone marrow transplantation. Gastroenterol Hepatol 2000; 23: 177-180.
-
(2000)
Gastroenterol Hepatol
, vol.23
, pp. 177-180
-
-
Alvarez, R.1
Banares, R.2
Casariego, J.3
Echenagusia, A.4
Simo, G.5
Alvarez, E.6
-
108
-
-
0035202855
-
Charcoal hemofiltration for hepatic veno-occlusive disease after hematopoietic stem cell transplantation
-
Tefferi A, Kumar S, Wolf RC, Lacy MQ, Inwards DJ, Gloor JM et al. Charcoal hemofiltration for hepatic veno-occlusive disease after hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 28: 997-999.
-
(2001)
Bone Marrow Transplant
, vol.28
, pp. 997-999
-
-
Tefferi, A.1
Kumar, S.2
Wolf, R.C.3
Lacy, M.Q.4
Inwards, D.J.5
Gloor, J.M.6
|